<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360958</url>
  </required_header>
  <id_info>
    <org_study_id>CCM S67/306</org_study_id>
    <nct_id>NCT00360958</nct_id>
  </id_info>
  <brief_title>Treatment of Severe Heart Failure by Ultrafiltration</brief_title>
  <official_title>Ultrafiltration for the Chronic Treatment of Severe Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <brief_summary>
    <textblock>
      Patients with severe congestive heart failure show increased fluid body content which is
      often resistant to conventional diuretic therapy. Therefore, chronic heart failure patients
      have frequent access to the emergency room and hospital for hemodynamic instability.
      Ultrafiltration is a simple renal replacement therapy which reduces fluid overload. The
      purpose of this study is to determine whether periodic ultrafiltration sessions maintain
      patients in stable clinical condition and reduce hospitalisations as well as access to
      emergency heart failure treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe heart failure (New York Heart Association [NYHA] III-IV) and fluid
      overload will be randomized to ultrafiltration (UF group) or conventional medical treatment
      (Control group). Patients follow-up at least monthly visit for one year. Ultrafiltration will
      be repeated during follow-up in case of body weight gain due to fluid accumulation.
      Ultrafiltration will be performed during short term hospitalization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of hospitalizations for heart failure</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>long term major adverse clinical events including death</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Severe Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ultrafiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrafiltration treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual HF treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrafiltration</intervention_name>
    <arm_group_label>Ultrafiltration</arm_group_label>
    <arm_group_label>Usual treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe heart failure (NYHA III-IV) with fluid overload

          -  Ejection fraction &lt; 40%

          -  Estimated fluid overload &gt; 4 kg

        Exclusion Criteria:

          -  Severe renal insufficiency

          -  Acute pulmonary edema and/or cardiogenic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piergiuseppe Agostoni, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiologico Monzino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Piergiuseppe Agostoni</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>ultrafiltration</keyword>
  <keyword>heart failure</keyword>
  <keyword>fluid overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

